From November 14 to 16, the First International Forum on Cell and Gene Therapy, jointly hosted by the Cell Medicine Branch of the China Food and Drug Enterprise Quality and Safety Promotion Association (CFDQP), the Vaccine and Biological Products Quality uation and Standards Professional Committee of CFDQP, the Guangdong Precision Medicine Application Association, and the Shenzhen Medical Doctor Association, was successfully concluded. This event, along with the Second Forum on Novel Vaccines and Biological Products Development and the High-Tech Achievement Exhibition of Outstanding Member Enterprises of CFDQP (collectively referred to as the "Two Forums and One Exhibition"), brought together distinguished scholars, entrepreneurs, and investors from the global biotechnology sector. Participants engaged in in-depth discussions on the latest scientific research achievements, industry dynamics, and future prospects in cell and gene therapy, injecting new momentum into the innovation-driven development of the biopharmaceutical industry and providing robust support for the sustained advancement of this field.

 The First International Forum on Cell and Gene Therapy & The Second Forum on Novel Vaccines and Biological Products Development

On the morning of November 15, the opening ceremony of the "Two Forums" was held in Conference Hall 2 of the Shenzhen World Exhibition and Convention Center. Distinguished guests attending the conference included 11 academicians: Zhang Xian'en, Ji Guangju, Zhang Dan, Cai Zhiming, He Yuerong, Mao Zhenbin, Chen Zhinan, Mark A. Kay, Wang Yutian, Lu Hongzhou, and Shi Qiong. In addition, over 100 experts, scholars, and technical professionals from major research institutions, higher education institutions, and the cell and gene therapy and vaccine R&D sectors participated in the presentation sessions, sharing their latest research findings and profound insights in the field of cell and gene therapy.

Professor Shi Yuanyuan, Vice Director of the Cell Medicine Branch and Chairman of Shenzhen Cell Valley, served as the Co-Executive Chair of the forum and presided over the opening ceremony and the national group standard release ceremony.

Under the meticulous preparation and leadership of Professor Chen Junhui of Peking University Shenzhen Hospital, Co-Executive Chair of the forum, the conference was successfully convened. Professor Chen briefly introduced the organizational structure and execution of the "Two Forums." The forum consisted of one main forum and six sub-forums, with total attendance exceeding 1,500 participants—a large-scale, high-level, and broadly influential professional technical event.

Co-Executive Chair of the Forum, Professor Lu Jiahai, Director of the Key Laboratory for Quality Monitoring and uation of Vaccines and Biological Products

Academician Mao Zhenbin, of the UN-International Academy of Ecology and Life Protection Sciences, President of CFDQP

Director Liu Xuejun, of the Health and Wellness Professional Committee of the China Society of Economic Reform

Professor Jiang Yuyang, Deputy Director of the Standing Committee of the Shenzhen Municipal People's Congress

National Group Standard Release Ceremony

       To advance the internationalization of China's cell and gene therapy field and fill gaps in industry standards, the forum released the Guidelines for the Preparation and Testing of Human Mesenchymal Stem Cell-Derived Exosomes, drafted under the leadership of Qingdao Haier Biomedical Technology Co., Ltd. and Peking University Shenzhen Hospital, as well as the Guidelines for the Development of (Cellular) Immunotherapy Products Based on mRNA-LNP Technology, drafted under the leadership of the Key Laboratory for Quality Monitoring and uation of Vaccines and Biological Products and Hunan Yuantai Biotechnology Co., Ltd. These standards are of significant and far-reaching importance in overcoming key technological bottlenecks constraining industry development, seizing the high ground in the new round of technological and industrial revolution, and advancing the industry toward high-quality development.

(Group photo of attending guests and representatives of the lead drafting units)

Main Forum: Frontiers in Biomedical Innovation

Professor Wu Zhihong, Chairman of the Expert Committee of the Cell Medicine Branch, Peking Union Medical College Hospital
Professor Wan Xiaochun, Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences
Researcher Zhang Yong, National Clinical Research Center for Respiratory Diseases

Professor Zhang Xian'en, School of Synthetic Biology, Shenzhen University of Advanced Technology, Academician of the American Institute for Medical and Biological Engineering – "Synthetic Biology Empowers New Quality Productive Forces"

Academician Mao Zhenbin, President of CFDQP – "Regulatory Science Promotes Innovative Development of Advanced Medical Products"

Professor Jiang Jianli, on behalf of Academician Chen Zhinan of the Chinese Academy of Engineering and the Air Force Medical University – "International Trends in Biomedical Technology and the Bioeconomy"

Dr. Jiang Ruhong, Chairman of ASC Therapeutics, on behalf of Professor Mark A. Kay, Member of the U.S. National Academy of Inventors

Professor Wang Jianjun, Interdisciplinary Research Center for Frontier Science, Technical Institute of Physics and Chemistry, Chinese Academy of Sciences

In the main forum, five top-tier experts with outstanding reputations in the biomedical field delivered in-depth presentations and exchanges on the theme of "Frontiers in Biomedical Innovation." From different perspectives, they shared their latest research findings, innovative concepts, and future development trends. Through these expert presentations, attendees gained insight into the latest developments in biomedicine and were inspired to engage in deeper thinking about technological innovation and industrial development.

02 Sub-Forum: Cell Preparation and Vector Technology Forum

On the afternoon of November 15, the Cell Preparation and Vector Technology Forum was held as scheduled. The forum was opened by Professor Shi Yuanyuan, Chairman of Shenzhen Cell Valley, and Dr. Xiang Hua, Co-founder and Deputy General Manager, who then led in-depth discussions and exchanges on the latest advances and future directions in cell preparation and vector technology.

Professor Wang Jianxun, Chief Scientist of Shenzhen Cell Valley, was invited to attend the forum and delivered an academic presentation on "Advances in Cellular Immunotherapy Research." Drawing on his profound expertise in immunology, Professor Wang engaged in in-depth discussions with participating experts and scholars, jointly exploring the latest trends in technological innovation and industry development in cellular immunotherapy. The forum also had the privilege of gathering Academician Zhang Dan, Co-Chairman of Jiangsu Puxin Biomedicine Co., Ltd., along with other experts and scholars in the field of cellular immunotherapy.

03 High-Tech Achievement Exhibition of Outstanding Member Enterprises of CFDQP

The 26th China International High-Tech Achievements Fair (Hi-Tech Fair) concluded successfully on November 16. In the biomedical sector, the Cell and Gene Therapy and Vaccine Forum and the High-Tech Achievement Exhibition of Outstanding Member Enterprises became a major highlight of this year's Hi-Tech Fair. Over the three-day exhibition, more than 15,000 visitors came to view the exhibits and engage in business discussions.

Shenzhen Cell Valley, as an outstanding enterprise in the cell and gene therapy field, was invited to participate. During the exhibition, Shenzhen Cell Valley attracted significant attention from visiting academicians and leaders. Chairman Professor Shi Yuanyuan provided them with a detailed introduction to Shenzhen Cell Valley's core advantages and business scope. As the only service provider in China capable of offering industrial-grade retroviral vectors for one-stop cell and gene therapy solutions, Shenzhen Cell Valley has established a standardized, GMP-grade industrial-scale production line for retroviral vectors (RVV) and CAR-T cell products. The company provides comprehensive services ranging from viral vector pipelines to cell product pipelines, IIT/IND/NDA regulatory application support, and industry talent training—building a mature, full-process, one-stop contract service system.

(Group photo of Chairman Professor Shi Yuanyuan with visiting academicians and leaders)

This grand event provided Shenzhen Cell Valley with a platform to showcase its capabilities, exchange ideas, and foster cooperation with related fields and international partners, fully demonstrating the company's development prospects in the cell and gene therapy field. Shenzhen Cell Valley will take this event as an opportunity to further accelerate its technological innovation and market expansion, contribute to the rapid development of the cell and gene therapy industry, and strive to make greater contributions to improving human health.